AgomAb Aligns With FDA On Design Of Phase 2b NOV-ERA For Ontunisertib In Crohn's Disease

AgomAb Therapeutics announced the study design for its Phase 2b NOV-ERA trial of Ontunisertib in fibrostenosing Crohn's disease, with the trial design aligned to FDA expectations. The update is a clinical-development milestone rather than a results readout, so the immediate market impact is likely limited. It is modestly supportive for the company’s pipeline, but does not yet provide efficacy or safety data.

Analysis

AgomAb Therapeutics announced the study design for its Phase 2b NOV-ERA trial of Ontunisertib in fibrostenosing Crohn's disease, with the trial design aligned to FDA expectations. The update is a clinical-development milestone rather than a results readout, so the immediate market impact is likely limited. It is modestly supportive for the company’s pipeline, but does not yet provide efficacy or safety data.